Table 2

Departures from additivity and multiplicativity of effects

Outcome		Departure from additivity				Departure from multiplicativity
Numbers		Measure	Estimate	Lower	Upper	Factor	OR	Lower	Upper
MACE-plus
N trials	3	RERI	−0.04	−0.22	0.14	Statin	0.80	0.69	0.92
N persons	23 874	AP	−0.06	−0.32	0.20	BPRx	0.92	0.80	1.05
N events	1560	S	1.14	0.61	2.12	Statin × BPRx	0.92	0.75	1.14
MACE
N trials	5	RERI	−0.09	−0.32	0.15	Statin	0.79	0.66	0.96
N persons	24 496	AP	−0.14	−0.51	0.23	BPRx	0.93	0.77	1.11
N events	857	S	1.31	0.56	3.05	Statin × BPRx	0.86	0.65	1.13
Stroke
N trials	5	RERI	0.02	−0.26	0.31	Statin	0.76	0.59	0.98
N persons	25 127	AP	0.05	−0.55	0.65	BPRx	0.70	0.54	0.90
N events	409	S	0.96	0.57	1.61	Statin × BPRx	0.90	0.60	1.35
Myocardial infarction
N trials	3	RERI	0.18	−0.28	0.64	Statin	0.66	0.42	1.03
N persons	13 958	AP	0.31	−0.49	1.11	BPRx	0.74	0.48	1.15
N events	144	S	0.70	0.31	1.56	Statin × BPRx	1.19	0.61	2.32
Death
N trials	5	RERI	−0.04	−0.33	0.25	Statin	0.97	0.79	1.19
N persons	15 851	AP	−0.04	−0.36	0.28	BPRx	0.97	0.79	1.20
N events	725	S	1.63	0.01	290.53	Statin × BPRx	0.96	0.71	1.30
Cardiovascular death
N trials	5	RERI	0.13	−0.23	0.49	Statin	0.85	0.63	1.14
N persons	15 055	AP	0.16	−0.28	0.59	BPRx	0.85	0.63	1.14
N events	348	S	0.57	0.14	2.27	Statin × BPRx	1.15	0.75	1.76

AP, attributable proportion due to interaction; BPRx, blood pressure-lowering treatment; Lower, lower 95% CI limit; MACE, major adverse cardiovascular events; N, number; RERI, relative excess risk due to interaction; S, synergy index15; Upper, upper 95% CI limit.